Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Julie R. Larsen"'
Autor:
Niels Ødum, Gitta Wörtwein, Tina Vilsbøll, Julie R. Larsen, Anders Fink-Jensen, Simon Fredholm, Mathias E. Jensen, Marco Møller
Publikováno v:
CNS spectrums. 27(3)
BackgroundTreatment with antipsychotics is associated with an increased risk of type 2 diabetes mellitus (T2D), and increased levels of inflammatory biomarkers are present in patients with T2D. We previously demonstrated that the glucagon-like peptid
Autor:
Mathilde S. L. Jakobsen, Louise Vedtofte, Ole Schjerning, Jens J. Holst, Camilla K Svensson, Jimmi Nielsen, Anders Fink-Jensen, Claus Thorn Ekstrøm, Christoph U. Correll, Sabine Bahn, Tina Vilsbøll, Julie R. Larsen, Hans R. Jespersen, Kamuran Koyuncu, Michelle I Jakobsen, Jakub Tomasik, Nitin Rustogi
Publikováno v:
Tomasik, J, Rustogi, N, Larsen, J R, Jakobsen, M I, Svensson, C K, Vedtofte, L, Jakobsen, M S L, Jespersen, H R, Koyuncu, K, Schjerning, O, Nielsen, J, Ekstrøm, C T, Correll, C U, Holst, J J, Vilsbøll, T, Bahn, S & Fink-Jensen, A 2020, ' Leptin Serum Levels are Associated With GLP-1 Receptor Agonist-Mediated Effects on Glucose Metabolism in Clozapine-or Olanzapine-Treated, Prediabetic, Schizophrenia Patients ', Schizophrenia Bulletin Open, vol. 1, no. 1, sgaa044 . https://doi.org/10.1093/schizbullopen/sgaa044
Background We previously demonstrated that the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide significantly reduced glucometabolic disturbances and body weight vs placebo in prediabetic, overweight, or obese schizophrenia-spectrum dis
Publikováno v:
Psychiatry Research. 296:113670
Schizophrenia is associated with a lowered bone mineral density. The antidiabetic and body weight lowering glucagon-like peptide-1 receptor agonist liraglutide has shown to mitigate overweight and impaired glucose tolerance associated with olanzapine
Autor:
Volkert Siersma, Niels de Fine Olivarius, Susanne Reventlow, Frans Boch Waldorff, Julie R. Larsen, Annette Sofie Davidsen
Publikováno v:
General Hospital Psychiatry. 38:42-52
Objective To assess the effectiveness of an intervention in Type 2 diabetic patients with concurrent psychiatric illness (PI) and compare this with the effectiveness in patients without PI. Method In the Diabetes Care in General Practice trial, 1381
Publikováno v:
Expert review of clinical pharmacology. 11(4)
The metabolic syndrome includes a constellation of several well-established risk factors, which need to be aggressively treated in order to prevent overt type 2 diabetes and cardiovascular disease. While recent guidelines for the treatment of individ
Autor:
Kristian Linnet, Camilla K Svensson, Anders Fink-Jensen, Sys Stybe Johansen, Jimmi Nielsen, Julie R. Larsen, Michelle I Jakobsen
Publikováno v:
Jakobsen, M I, Larsen, J R, Svensson, C K, Johansen, S S, Linnet, K, Nielsen, J & Fink-Jensen, A 2017, ' The significance of sampling time in therapeutic drug monitoring of clozapine ', Acta Psychiatrica Scandinavica, vol. 135, no. 2, pp. 159-169 . https://doi.org/10.1111/acps.12673
OBJECTIVE: Therapeutic drug monitoring (TDM) of clozapine is standardized to 12-h postdose samplings. In clinical settings, sampling time often deviates from this time point, although the importance of the deviation is unknown. To this end, serum con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44de1e8b5c5fc1293cf167df41881850
https://vbn.aau.dk/da/publications/735d0e5b-22d0-42fd-8e3f-ac20128abf4a
https://vbn.aau.dk/da/publications/735d0e5b-22d0-42fd-8e3f-ac20128abf4a
Autor:
Kamuran Koyuncu, Camilla K Svensson, Mathilde S. L. Jakobsen, Andreas Kjaer, Julie R. Larsen, Jens J. Holst, Louise Vedtofte, Claus Thorn Ekstrøm, Hans R. Jespersen, Tina Vilsbøll, Michelle I Jakobsen, Jimmi Nielsen, Peter Oturai, Ole Schjerning, Anders Fink-Jensen, Christoph U. Correll
Publikováno v:
Larsen, J R, Vedtofte, L, Jakobsen, M S L, Jespersen, H R, Jakobsen, M I, Svensson, C K, Koyuncu, K, Schjerning, O, Oturai, P S, Kjaer, A, Nielsen, J, Holst, J J, Ekstrøm, C T, Correll, C U, Vilsbøll, T & Fink-Jensen, A 2017, ' Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine-or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder : A Randomized Clinical Trial ', JAMA Psychiatry, vol. 74, no. 7, pp. 719-728 . https://doi.org/10.1001/jamapsychiatry.2017.1220
Importance: Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and ca
Autor:
Tina Vilsbøll, Louise Vedtofte, Anders Fink-Jensen, Andreas Kjaer, Julie R. Larsen, Peter Oturai, Jens J. Holst, Christoph U Corell
Publikováno v:
BMJ Open
Background Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major clinical problems among patients with antipsychotic treatment. Especially two of the most efficacious antipsychotics, clozapine and olanzapine, cause we